Latest news with #CompensationCommittee
Globe and Mail
2 days ago
- Business
- Globe and Mail
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 20,000 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 20,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $2.29 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16 th of the number of shares subject to the option on each quarterly anniversary of the employee's first day of employment, subject to the employee's continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee's first day of employment, subject to the employee's continued employment on such vesting date. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via an investigational eFlow ® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn: *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Yahoo
3 days ago
- Business
- Yahoo
ATEC to Report Second Quarter 2025 Financial Results on July 31, 2025
CARLSBAD, Calif., July 17, 2025--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducement Awards Granted As an inducement material to accepting employment with the Company, and in accordance with Nasdaq Listing Rule 5635(c)(4), ATEC today announced that the independent Compensation Committee of the Board of Directors has approved aggregate grants to 37 new employees (who are not executive officers) of, collectively, 61,096 restricted stock units ("RSUs") under the Company's 2016 Employment Inducement Award Plan. The RSUs will vest in equal annual installments on each of the first four anniversaries of the grant date, provided that the recipient remains continuously employed by ATEC as of such vesting date. In addition, the RSUs will vest fully upon a change of control of ATEC. View source version on Contacts Investor/Media Contact: Robert JuddInvestor Relations(760) 494-6790investorrelations@ Company Contact: J. Todd KoningChief Financial Officerinvestorrelations@ Sign in to access your portfolio
Globe and Mail
3 days ago
- Business
- Globe and Mail
ATEC to Report Second Quarter 2025 Financial Results on July 31, 2025
Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducement Awards Granted As an inducement material to accepting employment with the Company, and in accordance with Nasdaq Listing Rule 5635(c)(4), ATEC today announced that the independent Compensation Committee of the Board of Directors has approved aggregate grants to 37 new employees (who are not executive officers) of, collectively, 61,096 restricted stock units ('RSUs') under the Company's 2016 Employment Inducement Award Plan. The RSUs will vest in equal annual installments on each of the first four anniversaries of the grant date, provided that the recipient remains continuously employed by ATEC as of such vesting date. In addition, the RSUs will vest fully upon a change of control of ATEC.
Globe and Mail
3 days ago
- Business
- Globe and Mail
Airgain® Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Airgain, Inc. (NASDAQ: AIRG), a leading provider of advanced wireless connectivity solutions, today announced that it has granted inducement awards to one new employee who recently joined the Company. The awards were made on July 15, 2025, under Airgain's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Airgain as an inducement to join the company. The inducement awards to the new employee consist of an aggregate of 4,000 restricted stock units ('RSUs'). The RSUs shall vest over four years in substantially equal annual installments on August 15, 2026, 2027, 2028, and 2029, subject to the employee's continued service with the Company through each applicable vesting date. The awards were approved by the Compensation Committee of Airgain's Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to the new employee entering into employment with Airgain in accordance with Nasdaq Rule 5635(c)(4). The awards were not individually negotiated. About Airgain, Inc. Headquartered in San Diego, California, Airgain, Inc. (NASDAQ: AIRG) is a leading provider of advanced wireless connectivity solutions that drive cutting-edge innovation in 5G technology. We are committed to delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. Our mission is to connect the world through integrated, innovative, and optimized wireless solutions. Our diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. For more information, visit or follow us on LinkedIn and X.
Yahoo
03-07-2025
- Business
- Yahoo
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the 'Company'), today announced that, on June 30, 2025, it granted equity awards to two new non-executive employees as a material inducement to employment. The equity awards were granted under the Company's 2021 Inducement Plan, as amended, and were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards consisted of stock options to purchase an aggregate of 240,000 shares of the Company's common stock and 150,000 restricted stock units ('RSUs'). The stock options have an exercise price of $0.94, which is equal to the closing price of the Company's common stock on the grant date of June 30, 2025. The options vest over a period of four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in equal quarterly installments at the end of each quarter thereafter. The RSUs vest in four equal installments on the first, second, third and fourth anniversary of the grant date. All equity awards are subject to the employees' continued employment with the Company on the applicable vesting dates. About Opus Genetics The Company is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. The Company is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances. The Company is based in Research Triangle Park, NC. For more information, visit ContactsInvestorsJenny KobinRemy BernardaIR Advisory Solutionsir@ MediaKimberly HaKKH Source: Opus Genetics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
